Bupropion as a modulator of drug activity
Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
1. A method of treating major depression, comprising orally administering a dosage form once a day or twice a day to a human being in need thereof for at least 8 consecutive days, wherein the dosage form contains dextromethorphan and bupropion as the only therapeutically active compounds, which provides immediate release of dextromethorphan and sustained release of bupropion, wherein a total daily dose of about 200 mg to about 250 mg of the bupropion and a total daily dose of about 80 mg to about 110 mg of the dextromethorphan are orally administered to the human being; and wherein orally administering the dosage form is more effective than orally administering the same amount of the bupropion for 8 consecutive days in treating major depression.
2. The method of claim 1 , wherein the total daily dose of the dextromethorphan is 90 mg of dextromethorphan hydrobromide or a molar equivalent amount of another form of dextromethorphan.
3. The method of claim 2 , wherein about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, is orally administered twice a day.
4. The method of claim 3 , wherein the dosage form is orally administered twice a day.
5. The method of claim 4 , wherein the human being is an adult.
6. The method of claim 5 , wherein the human being is suffering from treatment-resistant depression.
7. The method of claim 5 , wherein the dosage form further comprises an excipient.
8. The method of claim 5 , wherein the dosage form further comprises a binder.
9. The method of claim 5 , wherein the dosage form further comprises a lubricant.
10. The method of claim 5 , wherein the dosage form further comprises a disintegrating agent.
11. The method of claim 3 , wherein the dosage form is orally administered twice a day for at least 14 days.
12. The method of claim 11 , wherein the human being is an adult.
13. The method of claim 12 , wherein the human being is suffering from treatment-resistant depression.
14. The method of claim 12 , wherein the dosage form further comprises an excipient.
15. The method of claim 12 , wherein the dosage form further comprises a binder.
16. The method of claim 12 , wherein the dosage form further comprises a lubricant.
17. The method of claim 12 , wherein the dosage form further comprises a disintegrating agent.
18. The method of claim 3 , wherein the dosage form is orally administered twice a day for at least 30 days.
19. The method of claim 18 , wherein the human being is suffering from treatment-resistant depression.
20. The method of claim 18 , wherein the human being is an adult.
21. The method of claim 20 , wherein the dosage form further comprises an excipient.
22. The method of claim 20 , wherein the dosage form further comprises a binder.
23. The method of claim 20 , wherein the dosage form further comprises a lubricant.
24. The method of claim 20 , wherein the dosage form further comprises a disintegrating agent.
25. The method of claim 2 , wherein the total daily dose of the dextromethorphan is orally administered in a single daily dose.
26. The method of claim 25 , wherein the single daily dose of the dextromethorphan is orally administered for at least 14 days.
27. The method of claim 25 , wherein the single daily dose of the dextromethorphan is orally administered for at least 30 days.
28. The method of claim 1 , wherein the human being is suffering from treatment-resistant depression.
29. The method of claim 1 , wherein the human being is an adult.